MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
13.52
-0.98 (-6.76%)
At close: Oct 14, 2025, 4:00 PM EDT
14.00
+0.48 (3.55%)
After-hours: Oct 14, 2025, 6:02 PM EDT
MBX Biosciences Employees
MBX Biosciences had 43 employees as of December 31, 2024. The number of employees increased by 16 or 59.26% compared to the previous year.
Employees
43
Change (1Y)
16
Growth (1Y)
59.26%
Revenue / Employee
n/a
Profits / Employee
-$1,791,140
Market Cap
604.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MBX News
- 15 days ago - MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewsWire
- 19 days ago - Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 19 days ago - MBX Biosciences, Inc. - Special Call - Seeking Alpha
- 19 days ago - MBX Biosciences Announces Pricing of Upsized Public Offering - GlobeNewsWire
- 22 days ago - MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market - Seeking Alpha
- 22 days ago - MBX Biosciences Announces Proposed Public Offering - GlobeNewsWire
- 22 days ago - MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension - GlobeNewsWire
- 25 days ago - MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 - GlobeNewsWire